CMTA is supporting a two-year research project examining hearing and balance signaling to strengthen outcome measures in future CMT clinical trials.
Hearing and Balance Biomarkers for Outcome Measure Development in CMT1A
With CMTA support of $141,000, researchers led by Gabriel Corfas, PhD, at the Kresge Hearing...
ACT-CMT: CMT1A Natural History Study, Long-Term Progression, and Biomarkers
With $1.2M in CMTA funding, the ACT-CMT study is tracking long-term CMT1A progression and advancing biomarker development to prepare for future clinical trials.
Measurement of muscle fat fraction in calf and thigh muscle in patients with CMT4J
With CMTA support of $149,443, researchers at Elpida Therapeutics are investigating muscle fat fraction (MFF)...
CMT2F Biomarkers and Outcome Measures
With CMTA support of $302,071, an international team of researchers from the Inherited Neuropathy Consortium...
2A Biomarkers and Outcome Measures
With CMTA support of $572,055, an international team of researchers from the Inherited Neuropathy Consortium,...
CMTX1 Biomarkers and Outcome Measures
With CMTA support of $529,971, an international team of researchers from the Inherited Neuropathy Consortium,...
1B Biomarkers and Outcome Measures
With CMTA support of $529,971, an international team of researchers from the Inherited Neuropathy Consortium,...
